Atherosclerosis
Atherosclerosis is characterized by the buildup of lipid-rich plaque and lesions on the interior lining of arteries, often leading to their narrowing and increased clot formation. This condition, influenced by lifestyle factors such as poor diet, lack of exercise, and smoking, can develop without symptoms but may eventually cause serious diseases like coronary artery disease, stroke, peripheral artery disease, and kidney disorders typically starting in middle age.
Health Outcomes
- Altered Circulating Metabolic Profile
- Altered NF-kappaB Signaling
- Altered Pro-Inflammatory Cytokine Levels
- Atherogenic Lipid Profile
- Changes in Inflammatory Markers
- Controlled Serum Cholesterol Levels
- Decreased HDL Cholesterol Level
- Delayed Cardiac Pathology
- Elevated Complement C3 Levels
- Elevated IL-6 Levels
- Elevated Interleukin-6 Levels
- Elevated Malondialdehyde Levels
- Elevated Redox Status
- Elevated Serum Lipoprotein Lipase Levels in Gilts
- Elevated Serum Metabolites in Response to Inflammation
- Elevated Serum TNF-α Levels
- Elevated TNF-α Expression Level
- Endothelial Cell Damage
- Enhanced Aggregation Abilities
- Enhanced Alternative Complement Activity
- Enhanced Anti-inflammatory Response
- Enhanced Antioxidant Bioaccessibility
- Enhanced Antioxidant Capabilities
- Enhanced Antioxidant Defense
- Enhanced Antioxidant Enzyme Activity
- Enhanced Antioxidant Levels
- Enhanced Antioxidant Response
- Enhanced Antioxidative Capacity
- Enhanced Cell Adherence
- Enhanced Cell Adhesion
- Enhanced Cell Viability Under Oxidative Stress
- Enhanced Endoplasmic Reticulum Stress Response
- Enhanced Folate Synthesis
- Enhanced Inflammation Resolution
- Enhanced Inflammatory Response
- Enhanced Leukocyte Recruitment
- Enhanced Lipid Metabolism in Adipose Tissue
- Enhanced Nitric Oxide Production
- Enhanced Polyphenol Levels
- Enhanced Pro-Inflammatory Cytokine Response
- Enhanced Protein Kinase C Activity
- Enhanced Radical Scavenging Ability
- Enhanced Reactive Oxygen Species Resistance
- Enhanced Reverse Cholesterol Transport
- Enhanced Serum Peroxidase Activity
- Enhanced Superoxide Dismutase Activity
- Extended Lifespan
- Extended Lifespan in Caenorhabditis elegans
- Identified ACE-Inhibitory Peptides
- Improved Aging-Related Changes
- Improved Anti-Aging Effects
- Improved Anti-Oxidative Effects
- Improved Antioxidant Activity
- Improved Antioxidant Capacity
- Improved Antioxidant Defense
- Improved Antioxidant Function
- Improved Antioxidant Levels
- Improved Antioxidant and Anti-Inflammatory Response
- Improved Antioxidative Capacity
- Improved Antioxidative Response
- Improved ApoB-100/ApoA-1 Ratio
- Improved Arginine Metabolism
- Improved Atherosclerosis-Related Cardiovascular Risk Markers
- Improved Auto-Aggregation Capability
- Improved Bioactivity
- Improved Biochemical Parameters
- Improved Blood Lipid Content
- Improved Blood Lipid Profile
- Improved Cardiometabolic Health
- Improved Cardioprotective Activity
- Improved Cardiovascular Disease Marker
- Improved Cardiovascular Disease Outcomes
- Improved Cardiovascular Function
- Improved Cardiovascular Health
- Improved Cell-Cell Signalling
- Improved Cholesterol Levels
- Improved Cholesterol Metabolism
- Improved Cholesterol Profile
- Improved Cholesterol Regulation
- Improved Cytoprotection During Oxidative Stress
- Improved Dyslipidemia
- Improved Elasticity
- Improved Endothelial Function Biomarker
- Improved Endothelial Health Marker Level
- Improved Endothelial Reactivity
- Improved Endothelium-Dependent Vasodilation
- Improved Endothelium-Dependent Vasodilation in Resistance Arteries
- Improved Endothelium-Independent Microvascular Vasodilation
- Improved Fatty Acid Composition
- Improved Fibrinolytic Activity
- Improved Fish Chemical Composition
- Improved Flow-Mediated Dilation
- Improved Flow-Mediated Vasodilation
- Improved Free Radical Scavenging Activity
- Improved Glutathione Level
- Improved Glutathione Peroxidase Activity
- Improved Glutathione Redox Ratio
- Improved Glycerophospholipid Metabolism
- Improved High-Density Lipoprotein Level
- Improved Imaging Findings
- Improved Inflammation Homeostasis
- Improved Inflammatory Biomarkers
- Improved Inflammatory Marker Profile
- Improved Inflammatory Profile
- Improved Inflammatory Response
- Improved Inflammatory Status
- Improved LDL Cholesterol
- Improved LDL-C to HDL-C Ratio
- Improved Lipid Levels
- Improved Lipid Metabolism
- Improved Lipid Profile
- Improved Lipid Serum Homeostasis
- Improved Lipoprotein Subfraction Profile
- Improved Low-Density Lipoprotein Composition
- Improved Mean Arterial Pressure
- Improved Metabolome Profile
- Improved Monocyte Activation
- Improved Myocardial Strain Rate
- Improved Oxidative Metabolism Regulation
- Improved Oxidative Status
- Improved Oxidative Stress Levels
- Improved Oxidative Stress Marker
- Improved Oxidative Stress Resistance
- Improved Oxidative Stress Tolerance
- Improved Peripheral Inflammation
- Improved Peroxisome Proliferator-Activated Receptor Gamma Expression
- Improved Phagocytic Activity of Granulocytes
- Improved Plasma Cholesterol Clearance
- Improved Plasma Lipid Levels
- Improved Reactive Hyperemia Index
- Improved Redox Homeostasis
- Improved Redox Potential
- Improved Retinal Vascular Health
- Improved Serum Biomarkers
- Improved Serum Lipids
- Improved Serum Parameters
- Improved Stress-Strain Index
- Improved Superoxide Dismutase Activity
- Improved Superoxide Dismutase Level
- Improved TBARS Levels
- Improved Total Antioxidant Status
- Improved Total Cholesterol Levels
- Improved Vascular Endothelial Function
- Improved Vascular Function
- Improved Vascular Function in Offspring
- Improved Vasodilation
- Improved Waist-to-Hip Ratio
- Improved n-6 to n-3 PUFA Ratio
- Increased AMPK Activation
- Increased Adiponectin Levels
- Increased Antioxidant Activity
- Increased Antioxidant Capacity
- Increased Antioxidant Enzyme Levels
- Increased Antioxidant Potential
- Increased Apolipoprotein E Levels
- Increased Arginine/ADMA Ratio
- Increased Bioactivity
- Increased Bioavailability of Phenolics
- Increased Bone Marrow Myelopoiesis
- Increased C-Reactive Protein Levels
- Increased CD163+ Macrophage Density
- Increased CD68 to CD163 Ratio
- Increased CD68+ Macrophage Density
- Increased Catalase Activity
- Increased Catalase Expression
- Increased Catalase Level
- Increased Cell Adhesion
- Increased Cellular Adhesion
- Increased Circulating Vitamin K2 Levels
- Increased Complement C3 Level
- Increased Conjugated Linoleic Acid Production
- Increased Cysteine Level
- Increased ER Stress-Associated Proteins
- Increased Eicosapentaenoic Acid Level
- Increased Endogenous Acrolein Formation
- Increased Endothelial Nitric Oxide Synthase Activity
- Increased Endothelial Progenitor Cell Count
- Increased Expression of CD206
- Increased Expression of Junctional Adhesion Molecule 2
- Increased Expression of Oxidation-Related Gene
- Increased F2-Isoprostane Level
- Increased Fecal Cholesterol Levels
- Increased Ferric Reducing Ability of Plasma
- Increased High-Density Lipoprotein Cholesterol
- Increased Homocysteine Level
- Increased Hydrogen Peroxide Production
- Increased Inflammatory Cytokines
- Increased Inflammatory Response
- Increased Inhibition of Lipid Oxidation
- Increased Interleukin-1 Beta Production
- Increased Interleukin-6 Production in Macrophages
- Increased KLF4 Protein Levels
- Increased LDL Cholesterol Level
- Increased Lipid Oxidation
- Increased Malondialdehyde Levels
- Increased MicroRNA-146a Expression
- Increased Milk Alpha-Carotene Concentration
- Increased Myeloperoxidase Activity
- Increased NRF2 Levels
- Increased Naringenin Level
- Increased Nattokinase Activity
- Increased Nitrate Level
- Increased Nitric Oxide Bioavailability
- Increased Nitric Oxide Metabolite Levels in Metabolic Syndrome Patients
- Increased Nitric Oxide Synthase Activity
- Increased Nrf2 Protein Content
- Increased Osteoprotegerin Immunostaining
- Increased Oxidative Stress
- Increased Oxidative Stress Tolerance
- Increased PPAR-γ Activity
- Increased PTGS2 Expression
- Increased Paraoxonase 1 Enzyme Activity
- Increased Plasma ApoA-V Levels
- Increased Plasma Haptoglobin Levels
- Increased Plasma Nitric Oxide Levels
- Increased Plasma Omega-3 Fatty Acids
- Increased Plasminogen Activator Inhibitor-1 Level
- Increased Polyphenol Level
- Increased Pro-inflammatory Cytokine Production
- Increased Pro-inflammatory Cytokine TNFα Levels
- Increased Production of ACE-Inhibitory Peptides
- Increased Reactive Oxygen Species Production
- Increased Reactive Oxygen Species Response
- Increased SalA-like Inhibitory Activity
- Increased Serum Amyloid Protein
- Increased Serum Antioxidant Enzyme Levels
- Increased Serum Antioxidant Levels
- Increased Serum Metabolites to Combat Inflammation
- Increased Serum Triglycerides
- Increased Serum Tumor Necrosis Factor-α Levels
- Increased Shear Force
- Increased Soluble Receptor of Advanced Glycation End Products
- Increased Soluble Vascular Cell Adhesion Molecule-1 Level
- Increased TNF-alpha Levels in Macrophages
- Increased Total Thiol Level
- Increased Tumor Necrosis Factor-Alpha Levels
- Increased Viable Cell Antioxidant Activity
- Increased n-3 Polyunsaturated Fatty Acid Levels
- Induced Health-Related Benefits
- Induction of Browning of White Adipose Tissue
- Inhibited Absorption of Advanced Glycation End-products (AGEs)
- Inhibited Lipid Oxidation
- Mimicked Dietary Restriction Effects
- Mitigated Cardiac Injury from Myocardial Infarction
- Modulated Inflammation and Coagulation Interaction
- Modulated Inflammatory Cytokine Levels
- Modulated PPAR/SREBP Pathway
- Multiple Health-Promoting Effects
- No Change in High Density Lipoproteins
- No Change in Major Cardiovascular Event
- No Improvement in Total Cholesterol
- No Reduction in Meat Cholesterol Levels
- No Significant Acute Effect on Calcium Metabolism
- No Significant Change in Total Cholesterol
- No Significant Change in Triglyceride Levels
- No Significant Effect on Diarrhea
- Normalized Lipid Metabolism
- Normalized Lipid Profile
- Normalized Serum IL-1β Levels
- Normalized Serum Lipid Levels
- Normalized Triglyceride
- Prevention of Aberrant Inflammatory Response
- Prevention of Cardiovascular Diseases
- Prevention of Hypercholesterolemia
- Protection Against Oxidative Stress
- Reduced 25-Hydroxycholesterol Level
- Reduced 25-Hydroxycholesterol to Total Cholesterol Ratio
- Reduced 27-Hydroxycholesterol to Total Cholesterol Ratio
- Reduced 8-Isoprostane Level
- Reduced Adipocyte Senescence
- Reduced Advanced Glycation End Product Level
- Reduced Adverse Physiometabolic Effects
- Reduced Age-Related Inflammation
- Reduced Aging-related Changes
- Reduced Angiogenesis
- Reduced Aortic Inflammation
- Reduced Aortic Superoxide Levels
- Reduced Aortic Thickness
- Reduced Apelin Gene Expression
- Reduced Apo B to Apo A1 Ratio
- Reduced Apolipoprotein B Levels
- Reduced Apolipoprotein B to A-1 Ratio
- Reduced Apolipoprotein B-100
- Reduced Apolipoprotein B-100 to Apolipoprotein A-1 Ratio
- Reduced Arterial Calcifying Lesion Development
- Reduced Arterial Stiffness
- Reduced Atherogenic Index
- Reduced Atherosclerosis
- Reduced Atherosclerosis Progression
- Reduced Atherosclerosis Risk Factors
- Reduced Atherosclerotic Cardiovascular Disease Event
- Reduced Atherosclerotic Lesion Size
- Reduced Atherosclerotic Plaque Formation
- Reduced Augmentation Index
- Reduced Blood Cholesterol
- Reduced Blood Lipid Levels
- Reduced Blood Stream Cholesterol
- Reduced Body Fat
- Reduced Carboxymethyl Lysine
- Reduced Cardiac Event
- Reduced Cardiac Injury
- Reduced Cardiovascular Disease Mortality
- Reduced Cardiovascular Dysfunction
- Reduced Cardiovascular Event
- Reduced Catalase Activity
- Reduced Cellular Senescence
- Reduced Central Blood Pressure
- Reduced Cerebral Blood Flow
- Reduced Cerebral Blood Flow Velocity
- Reduced Cerebrovascular Disease Mortality
- Reduced Chemokine Ligand 16 Level
- Reduced Cholesterol Metabolism
- Reduced Contrast-Induced Acute Kidney Injury
- Reduced Cumulative Morbidity Rates
- Reduced Dephosphorylated-Uncarboxylated Matrix Gla Protein Level
- Reduced Dietary Advanced Glycation End Product Intake
- Reduced Dyslipidemia Parameters
- Reduced Expression of Inflammation-Related Genes
- Reduced F2-Isoprostanes
- Reduced Ferroptosis
- Reduced Flavonifractor Abundance
- Reduced Flavonoid Levels
- Reduced Free Radical Levels
- Reduced Glutathione Loss
- Reduced Glycation End Product Accumulation
- Reduced Glycative Stress Marker Level
- Reduced HDL Cholesterol
- Reduced HDL Cholesterol Level
- Reduced HDL Levels
- Reduced HIF-1α Level
- Reduced HMG-CoA Reductase Inhibition
- Reduced Harmful Lipid Levels
- Reduced High-Density Lipoprotein (HDL) Cholesterol
- Reduced High-Density Lipoprotein Cholesterol Level
- Reduced High-Sensitivity C-Reactive Protein Level
- Reduced Homocysteine Level
- Reduced Hydrogen Sulfide Level
- Reduced Hydroperoxide Levels
- Reduced Hypercholesterolemia
- Reduced Hypercholesterolemia Incidence
- Reduced Hyperlipidemia Symptoms
- Reduced ICAM-1 Level
- Reduced IL-1β Levels
- Reduced IL-6 Levels
- Reduced IL-6 Secretion
- Reduced IkappaB Alpha Degradation
- Reduced Immunoinflammatory Markers
- Reduced Incidence of Cardiovascular Disease
- Reduced Inflammation Markers
- Reduced Inflammatory Biomarker Level
- Reduced Inflammatory Cytokines (TNF-α, IFN-γ, IL-6)
- Reduced Inflammatory Markers
- Reduced Inflammatory Molecules
- Reduced Inflammatory Parameters
- Reduced Inflammatory Pathways
- Reduced Insulin/IGF-1 Signaling
- Reduced Interleukin-1β Levels
- Reduced Interleukin-6 Levels
- Reduced Intimal Thickening
- Reduced Ischemic Heart Disease Mortality
- Reduced LDL Cholesterol
- Reduced LDL Levels
- Reduced LDL Oxidation
- Reduced Lesion Size
- Reduced Levels of Pro-Inflammatory Cytokines (IL-1β, IL-6, IFN-γ, TNF-α)
- Reduced Lipid Deposition
- Reduced Lipid Levels
- Reduced Lipid Oxidation
- Reduced Lipid Profiles
- Reduced Low-Density Lipoprotein Cholesterol
- Reduced Low-Density Lipoprotein Level
- Reduced Low-Grade Inflammation
- Reduced Lymphocytic Genome Damage
- Reduced MCP-1/CCL2 Levels
- Reduced MPO Levels
- Reduced Malonaldehyde Levels
- Reduced Malondialdehyde Generation
- Reduced Metabolic Inflammation
- Reduced Monocyte Adhesion
- Reduced Monocyte Chemoattractant Protein-1 Level
- Reduced Mortality Risk
- Reduced Myeloperoxidase (MPO) Concentration
- Reduced Myeloperoxidase Activity
- Reduced Myeloperoxidase Levels
- Reduced Myocardial Injury
- Reduced NADPH Oxidase Activity
- Reduced NF-kappaB-DNA Binding
- Reduced Neutrophil Extracellular Trap Formation
- Reduced Nitric Oxide Level
- Reduced Nitric Oxide Production
- Reduced Non-Communicable Disease Risk
- Reduced Non-HDL Cholesterol
- Reduced Non-High-Density Lipoprotein Cholesterol
- Reduced Non-Infectious Complication Morbidity
- Reduced Nonclassical Monocyte Frequency
- Reduced Nuclear Factor Erythroid 2-Related Factor 2 Level
- Reduced Nuclear Factor Kappa B Activation
- Reduced Nuclear Factor Kappa-B Level
- Reduced Oxidative Damage
- Reduced Oxidative Stress
- Reduced Oxidative Stress Index
- Reduced Oxidative Stress Marker Level
- Reduced Oxidative Stress Markers
- Reduced Oxidative Tissue Injury
- Reduced Oxidized Low-Density Lipoprotein Level
- Reduced Peripheral Inflammation
- Reduced Plant Sterols
- Reduced Plaque
- Reduced Plasma CRP Levels
- Reduced Plasma Homocysteine Levels
- Reduced Plasma Malondialdehyde Levels
- Reduced Platelet Function Marker Level
- Reduced Post-Exercise Serum Amyloid A Increase
- Reduced Postprandial Triacylglycerol Response
- Reduced Postprandial Triglyceride Level
- Reduced Pro-Inflammatory Factor TNF-α
- Reduced Pro-inflammatory Gene Transcription
- Reduced Pro-inflammatory Mediator Levels
- Reduced Pro-inflammatory to Anti-inflammatory Factor Ratio
- Reduced Proinflammatory Signaling
- Reduced Proportion of Volunteers with At Least One CID
- Reduced Protein Oxidation
- Reduced Reactive Oxygen Species Formation
- Reduced Release of Inflammatory Mediators (TNF-α, IL-6, IL-1β, IL-10)
- Reduced SCD1 Activity
- Reduced Saturated Fatty Acids in Breast Meat
- Reduced Senescence-Associated Secretory Phenotype
- Reduced Serum Amyloid A Levels
- Reduced Serum C-reactive Protein Levels
- Reduced Serum Cholesterol Levels
- Reduced Serum Inflammatory Factors
- Reduced Serum LDL Levels
- Reduced Serum LPS Levels
- Reduced Serum Lipid Levels
- Reduced Serum MDA Concentrations
- Reduced Serum Malondialdehyde Levels
- Reduced Serum Total Cholesterol Levels
- Reduced Soluble CD14
- Reduced Soluble Receptor of Advanced Glycation End Product Level
- Reduced Soluble VCAM-1 Levels
- Reduced Stroke Mortality Risk
- Reduced Symptoms Associated with High-Fat Diet
- Reduced Symptoms of High-Fat Diet Pathologies
- Reduced Systemic Inflammatory Marker
- Reduced Systemic Inflammatory Response
- Reduced TBARS Levels
- Reduced TMAO Production
- Reduced Thrombosis
- Reduced Thromboxane A2 Level
- Reduced Tissue Inhibitor of Metalloproteinase 1 Level
- Reduced Total Cholesterol Levels
- Reduced Total Cholesterol to HDL Cholesterol Ratio
- Reduced Total Lipid Levels
- Reduced Triglyceridemia
- Reduced Trimethylamine N-oxide Levels
- Reduced Urinary 8-Isoprostane Level
- Reduced Vascular Damage
- Reduced Vascular Permeability
- Reduced Vascular Restenosis
- Reduced Vascular Stiffness
- Reduced Visfatin Level
- Reduced Waist-to-Height Ratio
- Reduced Yolk Cholesterol Content
- Reduced hsCRP Level
- Regulated Blood Lipid Levels
- Regulated Inflammation
- Regulated Inflammatory Cytokines
- Regulated Inflammatory Responses
- Regulated Lipid Metabolism
- Regulated Lipid Metabolism in Epididymal Fat Pads
- Regulated Oxidative Stress
- Reproduced Protective Effect via Extracellular Vesicles
- Restored HDL Levels
- Restored Lipid Metabolism
- Restored SOD Activity Levels
- Safe Administration
- Stabilized Cell Membranes
- Stabilized Plasma Cholesterol Levels
- Stable High-Density Lipoprotein Cholesterol Level
- Stable Plasma Cholesterol Levels
- Stable Systemic Inflammatory Response
- Supported Physiological Function in Elderly
- Suppressed PPAR/SREBP Pathway Gene Activity
- Sustained Anti-Inflammatory Gene Transcription
- Unchanged Monocyte Chemoattractant Protein-1 Levels
- Upregulated Macrophage Inhibitory Factor